RVMDHealthcare · BiotechnologyThe 25 Wall Street analysts covering Revolution Medicines, Inc. hold a median 12-month price target of $260 — +36.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 28 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Revolution Medicines, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.
Size (6): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on RVMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +36.6% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Oct 2026 | TD Cowen | Reiterates | Buy | $250 |
| 19 Oct 2026 | Truist Securities | Maintains | Buy | $240 → $241 |
| 16 Oct 2026 | William Blair | Initiates | Outperform | — |
| 15 Oct 2026 | Needham | Reiterates | Buy | $275 |
| 14 Oct 2026 | RBC Capital | Maintains | Outperform | $259 → $260 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | $251 → $259 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | — |
| 7 Oct 2026 | Truist Securities | Maintains | Buy | $239 → $240 |
| 7 Oct 2026 | Truist Securities | Maintains | Buy | — |
| 28 Sept 2026 | Brookline Capital | Initiates | Buy | $318 |
| 28 Sept 2026 | Brookline Capital | Initiates | Buy | — |
| 24 Sept 2026 | Goldman Sachs | Reinstates | Buy | $267 |
| 21 Sept 2026 | B of A Securities | Maintains | Buy | — |
| 21 Sept 2026 | B of A Securities | Maintains | Buy | $225 → $265 |
| 10 Sept 2026 | Morgan Stanley | Initiates | Overweight | $255 |
| 10 Sept 2026 | Morgan Stanley | Initiates | Overweight | — |
| 9 Sept 2026 | Stifel | Maintains | Buy | $215 → $230 |
| 9 Sept 2026 | Stifel | Maintains | Buy | — |
| 31 Aug 2026 | Needham | Maintains | Buy | — |
| 31 Aug 2026 | Needham | Maintains | Buy | $240 → $275 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RVMD appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Revolution Medicines, Inc. returned +227.9% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 98% of US stocks
Cheaper than 6% of US stocks
Cheaper than 91% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 16% of US stocks
Higher than 14% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Revolution Medicines, Inc. has a market value of $39.9B and an enterprise value of $37.2B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$1.8B.
Diluted earnings per share, trailing twelve months: $−8.82.
Free cash flow in the twelve months to 30 June 2026: −$1.6B.
Trailing P/E: −31.7×; forward P/E: −32.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Revolution Medicines, Inc. employs 883 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Revolution Medicines, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The Motley Fool reports that Revolution Medicines’ stock has risen more than ninefold over three years, driven by excitement about its cancer drug Rasonque.
Why it matters — The report connects RVMD’s stock performance to investor enthusiasm for Rasonque.
On CNBC’s “Mad Money Lightning Round,” Jim Cramer said Penguin Solutions sells at a low multiple and that he does not mind low-multiple technology stocks because they tend not to get hurt as much as others.
Why it matters — The excerpt discusses Penguin Solutions, not Revolution Medicines, so it provides no company-specific information for RVMD watchers.
Duquesne Family Office increased its stake in Revolution Medicines during the second quarter. The company earned approval in the third quarter for an innovative pancreatic cancer medicine.
Why it matters — RVMD watchers may note both the reported increase in Duquesne’s position and the subsequent regulatory approval.
Revolution Medicines announced that CEO and chairman Mark A. Goldsmith will participate in two upcoming investor conferences in November 2026.
Why it matters — The announcement provides RVMD watchers with information about upcoming investor-facing appearances by the company's chief executive.
Revolution Medicines reported exploratory Phase 3 RASolute 302 subgroup analyses presented at ESMO 2026. RASONQUE showed an overall survival benefit versus chemotherapy across evaluated RAS genotypes, chemotherapy regimens and prior-treatment settings in previously treated metastatic pancreatic cancer.
Why it matters — The findings add subgroup evidence on RASONQUE’s overall survival results in previously treated metastatic pancreatic cancer.
The 25 Wall Street analysts covering Revolution Medicines, Inc. have a median 12-month price target of $260, with estimates ranging from $179 to $320. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 25 analysts covering Revolution Medicines, Inc., 24 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Revolution Medicines, Inc. 49 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Revolution Medicines, Inc. ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 25 analysts implies +36.6% from the last close, and Ticker Nerd's factor model ranks Revolution Medicines, Inc. 49 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Revolution Medicines, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RVMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $179 to $320 over the next 12 months.
Revolution Medicines, Inc. returned +227.9% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers.
The most recent item we track (The Motley Fool, 29 Oct 2026): "Could Revolution Medicines Be a Millionaire-Maker Stock?". The Motley Fool reports that Revolution Medicines’ stock has risen more than ninefold over three years, driven by excitement about its cancer drug Rasonque.
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers. The company applies proprietary drug discovery capabilities to create small-molecule medicines designed to act on challenging RAS pathway targets, a central driver in many aggressive tumors. Its current pipeline includes RAS(ON) inhibitors and companion inhibitors being studied as monotherapies and in combination regimens to address cancers with specific RAS mutations and related pathway dependencies. Revolution Medicines concentrates on areas of high unmet medical need, including pancreatic, lung, and colorectal cancers, and its work is aimed at improving how these diseases are treated in modern oncology practice. Headquartered in Redwood City, California, and founded in 2014, Revolution Medicines occupies a specialized position in the biotechnology sector through its focus on advanced precision medicine approaches.
CEO Dr. Mark A. Goldsmith M.D., Ph.D. · 883 employees · United States · https://www.revmed.com
